Pfizer (PFE) is in early-stage talks to acquire cancer drugmaker Seagen (SGEN) in what could be a multi-billion dollar deal, The Wall Street Journal’s Jared S. Hopkins and Jonathan D. Rockoff report. According to people familiar with the matter, Seagen would be expected to command a premium over its market value of some $30B. Seagen was in advanced talks last year to be acquired by Merck (MRK) in a deal that would have been worth $40B or more, but the two sides failed to reach agreement. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE:
- Pfizer (NYSE:PFE) Could Buy Seagen to Bolster Oncology Portfolio
- FDA Virtual Vaccines & Related Biological Products Advisory Committee Meeting
- Pfizer treatment of pulmonary arterial hypertension gets FDA orphan designation
- Pfizer’s elranatamab receives FDA and EMA filing acceptance
- Pfizer: FDA accepts for review BLA for RSV vaccine candidate